Viritis

Cure Viral Diseases

RAISING

$300,000

In exchange for

30%
Share on facebook
Share on twitter
Share on linkedin

Industry

HELATH AND WELLNESS

Company size

2-5 employees

Patent

NO

Location

Israel

Languages

English, Hebrew

Overview

Viral diseases cause millions of deaths each year. Although vaccines are a viable solution, they are far from perfect. The process of creating a vaccine is lengthy, expensive, and difficult because each virus requires a specific vaccine and random mutations can harm the vaccine’s effectiveness.

We are developing an antiviral drug that can destroy the target virus at the cellular level without causing harm to the cell or the body.

In addition to our drug, we are changing the way modern medicine combats viral pandemics, from preventive to active treatment.

The Vision

To cure the world of viral diseases

The Product

We at Viritis have developed a new antiviral drug that can destroy pathogenic viruses at the cellular level without harming the cell itself.

Our product is an antiviral drug including our hybrid molecule and nanotechnology delivery mechanism. The molecule and therapeutic method are patentable to our knowledge.

The Team

Amit Turman

CEO

B.Sc. Biotechnology, Entrepreneur, acceleration programs manager, and business development specialist with more than six years of experience as a CEO and founder of several startup companies.

Amit Philosoph

Chief Scientist

Ph.D. in Molecular Virology and Pathology at the Hebrew University of Jerusalem. Researcher of Genetic Diseases in the Molecular Metabolic Department, Metabolic Disease Unit, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel Hashomer, Israel.

Aaron Wistouch

CFO

Institutional and capital markets finance expert. As an entrepreneur founded and led two financial ventures to successful capitations. Aaron worked for the chief comptroller at the Israeli Ministry of Economics.

The Problem & Solution

Pathogenic viruses are considered a major threat to world population health. The existing solution for viral diseases is antiviral drugs and vaccines, both limited in their therapeutic effects.

We at Viritis Ltd. developed a new anti-viral drug and delivering mechanism that has the ability to fight and hinder pathogenic viruses at the cellular level.

Attributes:

  • Strong affinity for viruses and only viruses
  • Reduces symptoms from the first use
  • Virtually no side effects
  • One drug may be used to treat several viruses
  • No lasting damage to the cell

The Market

Our solution is intended for all humans who suffer from viral diseases and to target healthcare systems and pharmaceutical companies.

Competition

Vaccines are the main and only solution against viral diseases, yet this solution has major shortcomings:

  • Each virus requires a specific vaccine
  • Creating a vaccine is an arduous and costly process
  • Random mutation reduces vaccine effectiveness
  • Immune deficiency and allergies

The Opportunity

Governments as well as the private sector are investing great sums of money in the development of antiviral drugs and treatments now more than ever.

Purpose of Equity

$300,000 for conducting POC testing and applying for a provisional patent

A D D M Y S T A R T U P
Qilindo Logo | the Startup Network
Interested in Viritis?

Contact them directly.